Loading
ACS BrightEdge (American Cancer Society)
BrightEdge is the American Cancer Society's own venture fund. It invests donated money in start-ups working on cancer and returns any gains to the charity's mission.
Overview
ACS BrightEdge is the impact venture capital arm of the American Cancer Society, investing philanthropic capital in early-stage companies developing cancer therapeutics, diagnostics, devices and care delivery tools, with returns recycled into the Society's research and patient programmes. It is one of the clearest examples of a disease charity acting as an investor rather than a grant-maker. Portfolio links in OnCo are derived from the startup records that name it.
Portfolio
6Portfolio (6)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Auron Therapeutics Newton, MA, US | Growth stage | biotech | Acute myeloid leukaemiaMyelodysplastic syndromes / neoplasms (MDS)Small-cell lung cancerNeuroendocrine and small-cell prostate cancer | Series B 2025, $27M |
| Cerula Care West Hartford, CT, US | Startup | cro services | Seed 2025, $4M | |
| Clasp Therapeutics Cambridge, MA, US | Startup | biotech | Series A 2024, $150M | |
| Naveris Waltham, MA, US | Acquired | diagnostics | Head and neck squamous cell carcinoma | Acquisition 2026, $160M |
| Predicta Biosciences Cambridge, MA, US | Startup | diagnostics | Multiple myelomaSmouldering multiple myeloma | Series A 2025, $23M |
| TailorMed New York, NY, US | Growth stage | ai software | none on record |
Connected
7Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
acsbrightedge.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/